AbbVie Reports First Outlook as an Independent Company (ABBV)

Pharmaceutical product manufacturer, AbbVie Inc[ABBV]] reported their first earnings outlook on Wedneday after their separation from Abbott.

Following the release of their arthritis medication, Humira ABBV has released their first outlook since the separation from Abbott Laboratories(ABT).

For FY2013, ABBV is expecting to see earnings in the range of $3.03 to $3.13 per share. Analysts expect to see EPS of $3.08.

The company reported that sales of Humira, which is one of the worlds best selling drugs, increased 23% in the fourth quarter to $2.68 billion.

Additionally, the company saw sales from testosterone-boosting drug, AndroGel rise by 41% after increasing advertisements on television.

AbbVie shares were down 35 cents, or -0.94% during Wednesday morning trading. The stock has increased 6% in the past year.

The Bottom Line
Shares of AbbVie Inc(AABV) have a yield of 4.30%, based on Tuesday’s closing price of $37.18.

AbbVie Inc(ABBV) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here